Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 mars 2020 08h00 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,...
04 mars 2020 08h00 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Announces Management Promotions

SOUTH SAN FRANCISCO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
19 févr. 2020 08h00 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Announces Upcoming Investor Conference Presentations

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
07 févr. 2020 06h45 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Announces Pricing of $75 Million Public Offering

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
04 févr. 2020 17h42 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Announces Proposed Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
07 janv. 2020 08h00 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
16 déc. 2019 08h00 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
11 déc. 2019 08h00 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
10 déc. 2019 08h00 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
04 déc. 2019 08h00 HE | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...

Page précédente